Olema Pharmaceuticals (OLMA) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Olema Pharmaceuticals (OLMA) had its price target raised by JPMorgan Chase & Co. from $55.00 to $58.00. They now have an "overweight" rating on the stock.
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
Olema Pharmaceuticals (OLMA) had its price target lowered by The Goldman Sachs Group, Inc. from $38.00 to $27.00. They now have a "buy" rating on the stock.
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting